Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].

The Korean journal of hepatology - 1 Mar 2010

Cheong Hong Ryeol, Woo Hyun Young, Heo Jeong, Yoon Ki Tae, Kim Dong Uk, Kim Gwang Ha, Kang Dae Hwan, Song Geun Am, Cho Mong

Abstract excerpt

BACKGROUND/AIMS: The combination therapy of peginterferon (PEG-IFN) and ribavirin is the standard treatment for hepatitis C virus (HCV) infection. However, few trials have involved patients with cirrhosis. The purpose of this study was to elucidate the efficacy and safety of treatment with PEG-IF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Interferon-alpha
Share to Interferon alpha-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Cirrhosis

Share to Neutropenia

Share to Platelet Count

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 20375641
DOI: 10.3350/kjhep.2010.16.1.38

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20375641-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].PMID 20375641Read ↗

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.Semantic proximity Read ↗

[Effectiveness and complications of combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C].Semantic proximity Read ↗

Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis.Semantic proximity Read ↗

Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.Semantic proximity Read ↗

[Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].Semantic proximity Read ↗

[Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C].Semantic proximity Read ↗

Management of HCV in cirrhosis-a rapidly evolving landscape.Semantic proximity Read ↗

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.Semantic proximity Read ↗

[Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study].Semantic proximity Read ↗

[Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV].Semantic proximity Read ↗

[Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection].Semantic proximity Read ↗

How to optimize HCV therapy in genotype 1 patients with cirrhosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.